Kevin Charles Gorman, Chief Executive Officer at NEUROCRINE BIOSCIENCES INC (NBIX), sold 25,776 shares at $116.79 ($3.0M) on 2021-02-08, disclosed to the SEC on 2021-02-09.
Seasonal sale ($3.0M) by Chief Executive Officer — this insider has traded NBIX in February in at least three consecutive prior years. Pattern-driven, low signal.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $114.16 | 2,422 | $276K | 9.2% |
| 2 | $114.16 | 2,422 | $276K | 9.2% |
| 3 | $116.71 | 3,248 | $379K | 12.6% |
| 4 | $116.71 | 3,248 | $379K | 12.6% |
| 5 | $116.74 | 4,343 | $507K | 16.9% |
| 6 | $116.74 | 4,343 |
| $507K |
| 16.9% |
| 7 | $116.79 | 2,875 | $336K | 11.2% |
| 8 | $116.79 | 2,875 | $336K | 11.2% |
| Total | $116.26 avg | 25,776 | $3.0M | 100% |
| Filing → |
| NBIX | SELL | 2025-08-11 | $26.9M | — | Filing → |
| XNCR | SELL | 2025-06-16 | $29K | — | Filing → |
| NBIX | SELL | 2025-05-29 | $2.3M | — | Filing → |